- Research from the CDC has found that the mRNA vaccines, currently made only by Pfizer-BioNTech and Moderna for COVID-19, reduce the risk of infection by 91 percent in people who are fully vaccinated.
- They also found that it reduces the risk by 81 percent in people who are partially vaccinated.
- The vaccines reduce the severity in illness in vaccinated people who still get COVID-19.
- The Johnson & Johnson vaccine isn’t an mRNA vaccine.
New research from the Centers for Disease Control and Prevention (CDC) has found that the messenger RNA (mRNA) vaccines used against the coronavirus reduce the risk of COVID-19 infection by 91 percent in people who are fully vaccinated. For people who are partially vaccinated, the reduced risk drops to 81 percent.
The study, which was released this month as a preprint on MedRxiv, also shows that the vaccines reduce the severity of illness in both fully and partially vaccinated people who develop COVID-19.
The vaccine clinical trials conducted in 2020 showed that the mRNA vaccines produced by Pfizer-BioNTech and Moderna were extremely effective at preventing COVID-19. Those findings are holding up in the real world as millions of people across the world get vaccinated.
“Now with the real life data we are seeing again and again in different studies that these vaccines are very effective,” Dr. Inci Yildirim, a Yale Medicine vaccinologist, pediatric infectious diseases specialist, and associate professor of pediatrics, told Healthline.
“Vaccinated individuals are protected from getting the infection and transmitting the infection to others.”
The study evaluated the health data of 3,975 healthcare workers, first responders, frontline workers, and essential workers.
The participants, who were more likely to be exposed to COVID-19 due to the nature of their jobs, took weekly SARS-CoV-2 tests for 17 weeks.
The diagnostic tests were conducted via self-collected nasal swabs that were then tested in a laboratory for SARS-CoV-2. The positive tests were further studied to determine the amount of viral load in the person’s nose and the how long they were shedding virus.
The researchers evaluated the data according to the participants’ vaccination status, the local rate of COVID-19 in their communities, and how strictly the participants used personal protective equipment (PPE).
They found that the vaccines reduced the risk of infection by 91 percent in people who were fully vaccinated, meaning 2 weeks past their second dose. The vaccines reduced the risk by 81 percent in people who were partially vaccinated. “Partially vaccinated” can mean anywhere from 14 days after their first dose to 13 days after their second dose.
The researchers also found that fully and partially vaccinated people who still developed COVID-19 were more likely to have milder illnesses compared to those who were unvaccinated.
On average, vaccinated people who got COVID-19 spent about 6 fewer days feeling sick and 2 fewer days sick in bed. Compared to unvaccinated people, those who had one or both doses of the shots also had a up to a 66 percent lower chance of developing symptoms like fever and chills.
Other studies have found that vaccinated people who contract the coronavirus have
Researchers are still working to understand how viral load correlates to infectivity, but evidence from varicella and influenza suggest lower viral loads are likely linked to reduced spread of infection.
The findings add to a growing collection of evidence showing that mRNA shots are both safe and effective.
“Given what we already know from previous studies, these data are not surprising. These vaccines have been proven to be safe and effective at preventing infection with COVID-19,” said Dr. Annabelle de St. Maurice, an assistant professor of pediatrics and co-chief infection prevention officer at UCLA Health.
According to de St. Maurice, it’s worth noting that the participants included in the study may differ from the general population “in terms of health, co-morbidities, and immune status.”
The mRNA vaccines teach our immune system to make a protein or even just a piece of a protein that then triggers the immune system. Once the immune system is triggered, it’s more prepared to attack the coronavirus and stop an infection from developing.
Choosing the right antigen (piece of the virus that the vaccine will help our bodies identify and attack) is crucial to the success of the vaccine, explained Yildirim.
“Spike protein that is the common target in both mRNA vaccines available has been studied since MERS and is a very good trigger for the immune system to get activated and produce neutralizing antibodies,” explained Yildirim.
“Although we have seen some mutations with the SARS-CoV-2 virus (the virus that causes COVID-19), scientists are still finding that the vaccines are highly effective,” said de St. Maurice.
Researchers will need to continue studying the safety and efficacy of the vaccines in the months and years ahead.
According to Yildirim, though we have plenty of data showing the shots are safe and effective, it’s important to remember we didn’t even know about SARS-CoV-2 before the end of December 2019.
“We are still learning how long the protection from the natural infection or the vaccination will last,” Yildirim said.
This information will help inform future vaccination campaigns and tell us whether we’ll need booster shots.
As of now, the takeaway is clear: The safest and most effective way to protect yourself against COVID-19 is to get vaccinated.
“These vaccines are safe and highly effective. As we see more of a return to normal and opening of social gatherings and other activities this summer and fall, it will be increasingly important for people to be vaccinated,” said de St. Maurice.
New research from the CDC has found that the messenger RNA (mRNA) vaccines used against the coronavirus reduce the risk of infection by 91 percent in people who are fully vaccinated and 81 percent in people who are partially vaccinated.
The shots also reduce the severity in illness in vaccinated people who get COVID-19, compared to people who are unvaccinated. Researchers will need to continue to study the shots in the months and years ahead to understand their durability and whether we may need booster shots.